Patents by Inventor Susan Mrose

Susan Mrose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
    Publication number: 20070249682
    Abstract: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
    Type: Application
    Filed: February 2, 2007
    Publication date: October 25, 2007
    Inventors: Zhongli Zheng, Mary Carter, YuSheng Liao, Lihong Sun, Leonid Kirkovsky, Susan Mrose, Yen-Ming Hsu, David Thomas, Gerald Shipps, Satish Jindal, George Lenz, Huw Nash
  • CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications
    Patent number: 7173046
    Abstract: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: February 6, 2007
    Assignee: Biogen, Inc.
    Inventors: Zhongli Zheng, Mary-Beth Carter, YuSheng Liao, Lihong Sun, Leonid Kirkovsky, Susan Mrose, Yen-Ming Hsu, David Thomas, Gerald W. Shipps, Jr., Satish Jindal, George R. Lenz, Huw M. Nash
  • Novel CD40 : CD154 binding interruptor compounds and use thereof to treat immunological complications
    Publication number: 20040067982
    Abstract: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
    Type: Application
    Filed: February 28, 2003
    Publication date: April 8, 2004
    Inventors: Zhongli Zheng, Mary-Beth Carter, YuSheng Liao, Lihong Sun, Leonid Kirkovsky, Susan Mrose, Yen-Ming Hsu, David Thomas, Gerald W. Shipps, Satish Jindal, George R. Lenz, Huw M. Nash